Dana-Farber
ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making
Premium
The framework, which ranks de-intensification biomarkers by evidence tiers, could give oncologists, patients, regulators, and payors a common system to guide their use.
Reveal Genomics, Dana-Farber Using HER2DX to Analyze Data in Three Breast Cancer Trials
The partners aim to improve understanding of early-stage HER2-positive breast cancer patients and gain insights into optimal treatment strategies.
Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute
The firm plans to develop novobiocin for homologous recombination-deficient cancers including those resistance to PARP inhibitors.
In Brief This Week: AstraZeneca, CytoDyn, BerGenBio, Bayer, Dana-Farber Cancer Institute, Kronos Bio
News items for the week of Nov 8, 2021.
SpringWorks Therapeutics Licenses EGFR Inhibitors From Dana-Farber, Inks Two R&D Partnerships
The firm has entered collaborations with both Stanford Medicine and Ab Magnitude to further develop the new portfolio of lung cancer therapeutics.
Mar 3, 2021
Jul 24, 2020